Skip to content

Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

Detection of Immune Cell Responses in Chronic HCV Patients Developing Hepatocellular Carcinoma After Treatment With Direct Acting Antiviral Drugs (DAAs)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03602703
Enrollment
42
Registered
2018-07-27
Start date
2018-07-01
Completion date
2019-09-01
Last updated
2020-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-Induced Liver Injury

Keywords

Direct acting antiviral drugs immune responses

Brief summary

Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC

Detailed description

Clinical and laboratory assessment with measurement of Child-Pugh and MELD scores to assess the severity of liver disease and measurement of alpha fetoprotein level for HCC cases will be done. Radiological assessment using abdominal ultrasound and triphasic CT will be done to determine the extent of the HCC and staging. Blood sample from all patients will be withdrawn. Plasma will be isolated and stored at - 20C and further analysis for a panel of cytokines, caspases and growth factors using ELISA will be monitored. Peripheral blood mononuclear cells (PBMCs) will be isolated using ficoll gradient method and will then be stored at -80C. B and T cell proliferation in response to specific antigens will also be investigated using CFSE staining assay followed by flow cytometry analysis for CD4, CD8 and PD-1. Cell cycle analysis and apoptosis will be detected using Annexin V/PI staining method and flow cytometry analysis. The phosphorylation and activation of cytoplasmic proteins will be tested using Western blot analysis.

Interventions

DIAGNOSTIC_TESTFlow cytometry and Western Blot analysis

Diagnostic tests

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients with HCC on top of HCV related liver cirrhosis either received treatment or not * Patients without HCC either received treatment or not . * Patients with chronic HCV as a control group either received treatment or not.

Exclusion criteria

* Patients with HCC who received any interventional treatment as alcohol injection, radiofrequency , TACE..etc * Patients with recurrent HCC after curative treatment.

Design outcomes

Primary

MeasureTime frameDescription
Pattern of immunity in patients with de novo HCC develped after treatment with DAAsTwo monthsDifference of B and T cells immune responses after treatment with DAAs between those who develop HCC and those who do not develop HCC

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026